These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 34185964)

  • 1. PK/PD modeling analysis for dosing regimen selection of isatuximab as single agent and in combination therapy in patients with multiple myeloma.
    Koiwai K; El-Cheikh R; Thai HT; Brillac C; Fau JB; Veyrat-Follet C; Risse ML; van de Velde H; Semiond D; Nguyen L
    CPT Pharmacometrics Syst Pharmacol; 2021 Aug; 10(8):928-940. PubMed ID: 34185964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exposure-response analyses for selection/confirmation of optimal isatuximab dosing regimen in combination with pomalidomide/dexamethasone treatment in patients with multiple myeloma.
    Rachedi F; Koiwai K; Gaudel-Dedieu N; Sebastien B; Thai HT; Brillac C; Fau JB; Nguyen L; van de Velde H; Veyrat-Follet C; Semiond D
    CPT Pharmacometrics Syst Pharmacol; 2022 Jun; 11(6):766-777. PubMed ID: 35355430
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma.
    Martin T; Baz R; Benson DM; Lendvai N; Wolf J; Munster P; Lesokhin AM; Wack C; Charpentier E; Campana F; Vij R
    Blood; 2017 Jun; 129(25):3294-3303. PubMed ID: 28483761
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isatuximab monotherapy in relapsed/refractory multiple myeloma: A Japanese, multicenter, phase 1/2, safety and efficacy study.
    Sunami K; Suzuki K; Ri M; Matsumoto M; Shimazaki C; Asaoku H; Shibayama H; Ishizawa K; Takamatsu H; Ikeda T; Maruyama D; Kaneko H; Uchiyama M; Kiguchi T; Iyama S; Murakami H; Takahashi K; Tada K; Macé S; Guillemin-Paveau H; Iida S
    Cancer Sci; 2020 Dec; 111(12):4526-4539. PubMed ID: 32975869
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Model-based simulation to support the approval of isatuximab alone or with dexamethasone for the treatment of relapsed/refractory multiple myeloma in Japanese patients.
    Thai HT; Koiwai K; Shitara Y; Kazama H; Fau JB; Semiond D; Veyrat-Follet C
    CPT Pharmacometrics Syst Pharmacol; 2023 Dec; 12(12):1846-1858. PubMed ID: 37002644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isatuximab plus pomalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma according to prior lines of treatment and refractory status: ICARIA-MM subgroup analysis.
    Bringhen S; Pour L; Vorobyev V; Vural F; Warzocha K; Benboubker L; Koh Y; Maisnar V; Karlin L; Pavic M; Campana F; Le Guennec S; Menas F; van de Velde H; Richardson PG
    Leuk Res; 2021 May; 104():106576. PubMed ID: 33839618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics.
    Harrison SJ; Perrot A; Alegre A; Simpson D; Wang MC; Spencer A; Delimpasi S; Hulin C; Sunami K; Facon T; Vlummens P; Yong K; Campana F; Inchauspé M; Macé S; Risse ML; van de Velde H; Richardson P
    Br J Haematol; 2021 Jul; 194(1):120-131. PubMed ID: 34036560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
    Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Isatuximab: A Review of Its Use in Multiple Myeloma.
    Frampton JE
    Target Oncol; 2021 Sep; 16(5):675-686. PubMed ID: 34351561
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
    Mikhael J; Richardson P; Usmani SZ; Raje N; Bensinger W; Karanes C; Campana F; Kanagavel D; Dubin F; Liu Q; Semiond D; Anderson K
    Blood; 2019 Jul; 134(2):123-133. PubMed ID: 30862646
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti-CD38 antibody isatuximab monotherapy for Japanese individuals with relapsed/refractory multiple myeloma: An update of the phase 1/2 ISLANDs study.
    Sunami K; Fuchida SI; Suzuki K; Ri M; Matsumoto M; Shimazaki C; Asaoku H; Shibayama H; Ishizawa K; Takamatsu H; Ikeda T; Maruyama D; Imada K; Uchiyama M; Kiguchi T; Iyama S; Murakami H; Onishi R; Tada K; Iida S
    Hematol Oncol; 2023 Aug; 41(3):442-452. PubMed ID: 36433829
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Joint modelling and simulation of M-protein dynamics and progression-free survival for alternative isatuximab dosing with pomalidomide/dexamethasone.
    Thai HT; Gaudel N; Cerou M; Ayral G; Fau JB; Sebastien B; van de Velde H; Semiond D; Veyrat-Follet C
    Br J Clin Pharmacol; 2022 May; 88(5):2052-2064. PubMed ID: 34705283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-Disease Interaction and Time-Dependent Population Pharmacokinetics of Isatuximab in Relapsed/Refractory Multiple Myeloma Patients.
    Fau JB; El-Cheikh R; Brillac C; Koiwai K; Mace N; Campana F; Semiond D; Nguyen L
    CPT Pharmacometrics Syst Pharmacol; 2020 Nov; 9(11):649-658. PubMed ID: 33021075
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The lymphocyte/monocyte ratio predicts the efficacy of isatuximab plus pomalidomide in multiple myeloma patients.
    Shimazu Y; Kanda J; Onda Y; Fuchida SI; Ohta K; Shimura Y; Kosugi S; Yamamura R; Matsuda M; Hanamoto H; Adachi Y; Anzai N; Hotta M; Fukushima K; Yagi H; Yoshihara S; Tanaka Y; Takakuwa T; Tanaka H; Shibayama H; Uoshima N; Hosen N; Ito T; Shimazaki C; Matsumura I; Kuroda J; Takaori-Kondo A; Hino M
    Cancer Immunol Immunother; 2024 May; 73(7):135. PubMed ID: 38758239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial.
    Moreau P; Dimopoulos MA; Mikhael J; Yong K; Capra M; Facon T; Hajek R; Špička I; Baker R; Kim K; Martinez G; Min CK; Pour L; Leleu X; Oriol A; Koh Y; Suzuki K; Risse ML; Asset G; Macé S; Martin T;
    Lancet; 2021 Jun; 397(10292):2361-2371. PubMed ID: 34097854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An evaluation of isatuximab, pomalidomide and dexamethasone for adult patients with relapsed and refractory multiple myeloma.
    Piggin A; Prince HM
    Expert Rev Hematol; 2021 May; 14(5):419-427. PubMed ID: 33945375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Final results of a phase 1b study of isatuximab short-duration fixed-volume infusion combination therapy for relapsed/refractory multiple myeloma.
    Usmani SZ; Karanes C; Bensinger WI; D'Souza A; Raje N; Tuchman SA; Sborov D; Laubach JP; Bianchi G; Kanagavel D; Saleem R; Dubin F; Campana F; Richardson PG
    Leukemia; 2021 Dec; 35(12):3526-3533. PubMed ID: 34050260
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial.
    Raab MS; Engelhardt M; Blank A; Goldschmidt H; Agis H; Blau IW; Einsele H; Ferstl B; Schub N; Röllig C; Weisel K; Winderlich M; Griese J; Härtle S; Weirather J; Jarutat T; Peschel C; Chatterjee M
    Lancet Haematol; 2020 May; 7(5):e381-e394. PubMed ID: 32171061
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isatuximab for the treatment of relapsed/refractory multiple myeloma.
    Richardson PG; Beksaç M; Špička I; Mikhael J
    Expert Opin Biol Ther; 2020 Dec; 20(12):1395-1404. PubMed ID: 33111607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EMA Review of Isatuximab in Combination with Pomalidomide and Dexamethasone for the Treatment of Adult Patients with Relapsed and Refractory Multiple Myeloma.
    Delgado J; Zienowicz M; van Hennik PB; Moreau A; Gisselbrecht C; Enzmann H; Pignatti F
    Oncologist; 2021 Nov; 26(11):983-987. PubMed ID: 34213061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.